Oncorus is generating next-generation immunotherapies to activate the immune system to target and destroy cancer cells. Oncorus’ approach differs from current therapies that activate not just T cells, but other key immune cells to significantly improve outcomes for cancer patients. To activate immune cells, Oncorus is identifying viral immunotherapies that possess attractive properties over other anti-tumor therapies. These properties include selective attack and potent destruction of tumor cells and broad immune stimulation by causing the presentation of multiple tumor-specific antigens. Oncorus is advancing two platforms, their intratumorally administered Herpes Simplex Virus platform and their intravenously delivered self-amplifying viral RNA platform to treat a broad spectrum of cancers.

<p>Oncorus is generating next-generation immunotherapies to activate the immune system to target and destroy cancer cells. Oncorus’ approach differs from current therapies that activate not just T cells, but other key immune cells to significantly improve outcomes for cancer patients. To activate immune cells, Oncorus is identifying viral immunotherapies that possess attractive properties over other anti-tumor therapies. These properties include selective attack and potent destruction of tumor cells and broad immune stimulation by causing the presentation of multiple tumor-specific antigens. Oncorus is advancing two platforms, their intratumorally administered Herpes Simplex Virus platform and their intravenously delivered self-amplifying viral RNA platform to treat a broad spectrum of cancers.</p>


Oncorus

Founded: 2015
Location: Cambridge, MA
Employee range: 51-100
Funding: 100-500M

About:

Jobs: